Treatment for reducing adverse events including chemotherapy discomfort and other conditions

Abstract

This disclosure relates to treatments for reducing the side effects associated with treatment of a medication or drug, such as a chemotherapy medication, being experienced by a patient. This may be accomplished by administering to a patient taking the medication, a buffered aqueous liquid having a pH of about 10 to about 11.5.

The invention claimed is: 
     
       1. A method for reducing an adverse event associated with use of a medication, comprising: administering to a patient taking the medication, a buffered aqueous liquid having a pH of about 10 to about 11.5, wherein the buffered aqueous liquid comprises sodium bicarbonate, sodium carbonate, and trisodium phosphate, wherein the adverse event is bone marrow suppression, vomiting, hair loss, thinned or brittle hair, a liver problem, an infection, increased risk of infection, a muscle pain, shortness of breath, headache, numbness, depression, skin dryness, itchiness, a vision change, anemia, neutropenia, thrombocytopenia, hepatotoxicity, kidney toxicity, nausea, fever, diarrhea, inflammation around an injection site, redness or swelling at an injection site, irritation at a site of injection, heart damage or tissue damage at a site of injection, heart disease or tissue death at a site of injection, constipation, bruising, petechiae, rigors, weakness, abnormally low potassium levels in the bloodstream, weight loss, rash, anaphylaxis, inflammation, inflammation of the mouth, inflammation of the inside of the mouth, inflammation of the skin, colon inflammation, tiredness, low platelets, low white blood cell counts, abdominal pain, a stomach cramp, cramping abdominal pain, low blood pressure, tumor lysis syndrome, heart failure, reversible posterior leukoencephalopathy syndrome, low blood cell levels, an electrolyte problem, an allergic reaction, a blood clot, a blood clotting problem, a heart problem, heart damage, cardiomyopathy, a hearing problem, a kidney problem, trouble walking, heart disease, loss of appetite, bleeding from the bladder, pulmonary fibrosis, a mouth ulcer, bleeding, loss of consciousness, lung disease, lung damage, neurotoxicity, mucositis, oral mucositis, fatigue, severe exhaustion, myalgia, chills, arthralgia, a mouth sore, breakdown of the skin inside the mouth, neuropathy, a psychiatric problem, fluid retention, gastrointestinal bleeding, rhinorrhea, epistaxis, toneless voice, dyspnea, epithelial necrosis, erythema, vesication, liver toxicity, liver disease, skin rash, immunosuppression, change in taste, pain in the joints of the arms or legs, changes in the color of the nails, tingling in the hands or toes, unusual bruising or bleeding, hand-foot syndrome, change in normal bowel habits, cough, sore throat, difficulty swallowing, dizziness, facial flushing, chest pain, mental fatigue, sleepiness, gastrointestinal toxicity, a hypersensitivity reaction, alopecia, leukopenia, stomatitis, asthenia, blood in urine, incontinence, painful or difficult urination, unusually frequent urination, lesions, photosensitivity, change in sensation, difficulty walking, neuropathic pain, breathlessness, indigestion, pain, a seizure, a hearing change, or a combination thereof. 
     
     
       2. The method of  claim 1 , wherein the medication is a chemotherapy medication. 
     
     
       3. The method of  claim 1 , wherein the buffered aqueous liquid is orally administered to the patient three times per waking day. 
     
     
       4. The method of  claim 3 , wherein the buffered aqueous liquid is administered separately from the medication that the patient is receiving. 
     
     
       5. The method of  claim 1 , wherein the buffered aqueous liquid is administered orally. 
     
     
       6. A method for reducing an adverse event associated with use of a medication, comprising: administering to a patient taking the medication, a buffered aqueous liquid having a pH of about 10 to about 11.5, wherein each ounce of the buffered aqueous liquid contains about 0.2 grams to about 0.6 grams total of sodium bicarbonate, sodium carbonate, and trisodium phosphate. 
     
     
       7. The method of  claim 6 , wherein the medication is a chemotherapy medication. 
     
     
       8. The method of  claim 6 , wherein the buffered aqueous liquid is orally administered to the patient three times per waking day. 
     
     
       9. The method of  claim 6 , wherein the buffered aqueous liquid is administered separately from the medication that the patient is receiving. 
     
     
       10. The method of  claim 6 , wherein the buffered aqueous liquid is administered orally. 
     
     
       11. A method for reducing an adverse event associated with use of a medication, comprising: administering to a patient taking the medication, a buffered aqueous liquid having a pH of about 10 to about 11.5, wherein the buffered aqueous liquid is orally administered to the patient in about 0.2 ounce to about 2 ounce increments three times per waking day, wherein the increments are spaced at intervals of about 4 to about 6 hours. 
     
     
       12. The method of  claim 11 , wherein the medication is a chemotherapy medication. 
     
     
       13. The method of  claim 11 , wherein the buffered aqueous liquid is orally administered to the patient three times per waking day. 
     
     
       14. The method of  claim 11 , wherein the buffered aqueous liquid is administered separately from the medication that the patient is receiving. 
     
     
       15. The method of  claim 11 , wherein the buffered aqueous liquid is administered orally.